Journal article
Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: Clinical activity and molecular markers
RL Piekarz, R Frye, M Turner, J Wright, S Allen, MH Kirschbaum, J Zain, M Prince, L Hutchins, LC Showe, WD Figg, T Fojo, SE Bates
Haematologica Reports | Published : 2006
Abstract
Histone deacetylase inhibitors induce changes in gene expression that lead to cellular differentiation and reversal of the transformed phenotype. In addition, acetylation of centromeric chromatin and non-histone proteins also likely plays a role in cytotoxicity due to romi depsin. Interest in clinical development of these agents has been spurred by the responses observed in patients with peripheral or cutaneous T-cell lymphoma to romidepsin, previously FK228 or depsipeptide.